A Phase 1, Open-Label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gaba-A Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of PF-06372865 In Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gaba-A Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of PF-06372865 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2014

At a glance

  • Drugs PF 6372865 (Primary)
  • Indications Pain
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
    • 08 Sep 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top